Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aerospan

- PMLiVE

Teva sells UK and Ireland assets to Intas Pharma for £603m

Generics portfolio and manufacturing facility gain set to double Indian firm’s UK sales

AstraZeneca AZ

AZ licenses inflammatory bowel disease drug to Allergan for $1.52bn

Will receive $250m upfront with a further $1.27bn if drug reaches market in two indications

- PMLiVE

How merging firms can manage culture change

Addressing the potential problems and finding the solutions

Sanofi reception

Sanofi eyes March approval for dupilumab in atopic dermatitis

Analysts suggest sales could reach $2.8bn annually if licensed in eczema and asthma

AstraZeneca AZ

AstraZeneca to explore link between epigenetics and respiratory diseases

Joins forces with Asthma UK, the British Lung Foundation and MRC Technology

AstraZeneca AZ

AZ hopes dosing will differentiate its severe asthma therapy

Plans to file benralizumab in EU and US by the end of the year spurred by phase III data

- PMLiVE

Nestlé Health Science buys medical device firm

Acquisition of UK's Phagenesis expected to be completed by 2019

- PMLiVE

Allergies and asthma

Reframing the conversation from disease burden to prevention and health promotion

- PMLiVE

Teva acquires Allergan’s generics operations in $38.8bn deal

Also discloses $500m agreement to purchase the Irish firm’s distribution business

- PMLiVE

Pfizer buys gene therapy specialist Bamboo

Expands pipeline with Duchenne muscular dystrophy candidate in deal worth $700m

- PMLiVE

New drugs breathe life into GSK’s respiratory business

Revlar/Breo and Anoro offset ongoing Seretide decline with new sales growth

- PMLiVE

Recordati snaps up Swiss pharma company Pro Farma

Follows group's recent acquisition of Italian firm Italchimici

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links